Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension

NCT07632898 is registered in ClinicalTrials.gov with Inhibikase Therapeutics as lead sponsor.

NCT NCT07632898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07632898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension
Lead sponsor
Inhibikase Therapeutics
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 23, 2026
Completion date
December 30, 2030
Enrollment
484 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)